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Abstract: Defective regulation of the Janus kinase-signal transducer and activator of transcription
(JAK-STAT) signalling pathway in cancers, haematological diseases and chronic
inflammatory conditions highlights its clinical significance. While several biologic and
small molecule therapeutics targeting this pathway have been developed, these have
several limitations. Therefore there is a need to identify new targets for intervention.
Suppressor of cytokine signalling (SOCS) proteins are a family of inducible inhibitors of
cytokine receptors that activate the JAK-STAT pathway. Here we propose that newly
identified mechanisms controlling SOCS function could be exploited to develop
molecularly targeted drugs with unique modes of action to inhibit JAK-STAT signalling
in disease.
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HIGHLIGHTS 
The JAK-STAT signalling system utilised by many cytokines and growth factors has 
recently been exploited to develop a range of new therapies for chronic inflammatory 
disease, autoimmune conditions and cancers. However there have several limitations, 
emphasising the need for more therapeutic options. 
 
JAK-STAT signalling is controlled by induction of SOCS proteins which act as part of 
a negative feedback loop to prevent sustained activation. 
 
Identification of new regulatory mechanisms and protein-protein interactions has 
revealed new targets for generating more selective drugs for the range of conditions 
resulting from hyperactivation of the JAK-STAT pathway. 
Palmer Highlights
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Abstract: Defective regulation of the Janus kinase-signal transducer and activator of 
transcription (JAK-STAT) signalling pathway in cancers, haematological diseases and 
chronic inflammatory conditions highlights its clinical significance. While several 
biologic and small molecule therapeutics targeting this pathway have been developed, 
these have several limitations. Therefore there is a need to identify new targets for 
intervention. Suppressor of cytokine signalling (SOCS) proteins are a family of 
inducible inhibitors of cytokine receptors that activate the JAK-STAT pathway. Here 
we propose that newly identified mechanisms controlling SOCS function could be 
exploited to develop molecularly targeted drugs with unique modes of action to inhibit 
JAK-STAT signalling in disease. 
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JAKs: significance, structure and signalling 
Cytokines and cytokine-activated signalling pathways are central players in the 
development of autoimmune disorders (see Glossary), such as rheumatoid 
arthritis (RA), chronic inflammatory diseases and cancers [1,2]. A particularly 
important group of cytokines are those which activate the Janus kinase-signal 
transducer and activator of transcription (JAK-STAT) pathway. The importance of 
the JAK-STAT pathway in immunity is neatly demonstrated by primary 
immunodeficiencies caused by inactivating mutations in specific JAK and STAT 
genes; these include severe combined immunodeficiency, due to inactivation of 
JAK3, and autosomal dominant IgE syndrome caused by dominant-negative 
mutations in STAT3 [1]. Therefore, therapeutic approaches to block JAK-STAT 
signalling using inhibitors of cytokine-receptor interactions have proved invaluable 
treatment options for patients with autoimmune disorders such as RA and psoriasis, 
while oral small molecule JAK inhibitors, which block signalling downstream of 
cytokine receptors, have been developed for management of RA, myeloproliferative 
neoplasms (MPNs), psoriatic arthritis and ulcerative colitis [2,3]. Here, we focus on 
recently discovered mechanisms involved in the regulation of JAK-STAT signalling 
and discuss how these could be exploited to develop new therapeutics to inhibit 
signalling in indications with enhanced JAK-STAT activation. 
Janus kinases (JAKs) comprise a family of four tyrosine (Tyr) kinases (JAK1-3, and 
Tyk2). JAKs interact with type I and type II cytokine receptors, which include receptors 
for interleukins, interferons (IFNs) and hormones such as leptin. As these receptors 
have no intrinsic enzymatic activity, preferential interaction with distinct JAK isoforms 
is required for downstream signalling. For example gp130 (the signal transducing 
component of the IL-6 receptor complex) associates with JAK1-2 and Tyk2, while IL-
2 receptor complexes specifically associate with JAK1 and JAK3 [2]. Each JAK protein 
comprises seven JAK-homology (JH) domains (JH1, kinase domain; JH2, 
pseudokinase (PK) domain, JH3-5, SH2 domain (although it cannot bind phospho-
Tyr residues), and JH6-7, N-terminal 4.1, ezrin, radixin, moesin (FERM) domain) 
(Figure 1A). While the FERM and SH2 domains mediate JAK interaction with 
membrane-proximal box1/2 regions of cytokine receptors, the PK domain restrains Tyr 
kinase activity by binding the kinase domain [4,5]. 
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Cytokine-receptor interaction triggers phosphorylation of receptor-associated JAKs on 
specific Tyr residues required to turn on kinase activity. Structural studies suggest 
cytokine-receptor ligation re-orientates JAK-receptor complexes so that JAKs become 
sufficiently close to allow trans-phosphorylation of activation loops present in their 
kinase domains (Figure 1A). Activated JAKs then Tyr phosphorylate bound cytokine 
receptor on specific residues to generate docking sites for SH2 domain-containing 
STAT proteins. Receptor-bound STATs are then phosphorylated on conserved Tyr 
residues within their C-terminal domains prior to dissociation from the receptor and 
formation of homo- or heterodimers. These translocate to the nucleus, bind target 
gene promoters and stimulate target gene transcription (Figure 1B). STATs comprise 
a family of seven proteins (STAT1-4, STAT5A, STAT5B, STAT6) and cytokine 
receptors preferentially activate distinct STATs. For example, gp130-utilizing 
cytokines preferentially activate STAT3 via phosphorylation on Tyr705, while IFN 
receptors activate STAT1 through Tyr701 phosphorylation (reviewed in [1]). 
 
JAK-STAT therapeutics and the need for new targets 
Hyperactivation of the JAK-STAT signalling pathway in haematological and solid 
tumour malignancies, MPNs and autoimmune disorders has driven the development 
of therapeutics targeting this pathway. Biologics that block IL-6 signalling include 
siltuximab (anti-IL-6 antibody), which is licenced for multicentric Castleman’s 
disease, and tocilizumab (anti-IL-6 receptor [IL-6R] antibody) which is approved for 
treatment of RA, juvenile idiopathic arthritis, giant cell arteritis and chimeric antigen 
receptor (CAR) T cell-induced cytokine release syndrome [6]. Biologics blocking 
other JAK-STAT-activating cytokines include IL-17 blocker secukinumab for 
management of psoriasis, psoriatic arthritis and ankylosing spondylitis [7], and anti-
IL-5 blocker mepolizumab for severe eosinophilic asthma and vasculitis [8]. 
In addition, three orally available small molecule first generation JAK inhibitors or 
“JAKinibs” (tofacitinib, baricitinib, and ruxolitinib) are licensed in Europe and the USA. 
Ruxolitinib is approved for management of intermediate or high-risk myelofibrosis (MF) 
and polycythaemia vera (PV) in patients intolerant of or resistant to cytoreductive 
therapy with hydroxycarbamide. While baricitinib is approved for RA, tofacitinib is 
licensed for treatment of RA, active psoriatic arthritis and, most recently, moderate to 
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severely active ulcerative colitis [9]. Each drug targets the ATP-binding site in the 
kinase domain [9]. 
While effective, current JAK-STAT-targeted therapies have several drawbacks. For 
example, tociluzimab is associated with adverse effects such as anaemia, headaches 
and increased risk of infection. Due to conservation of primary sequences between 
kinase domain ATP-binding sites, first generation JAKinibs are non-selective inhibitors 
of multiple JAK isoforms. Therefore, they are associated with increased susceptibility 
to infections, particularly by herpes zoster, due to suppression of IFN-stimulated anti-
viral signalling [10]. JAKinibs can also cause thrombocytopenia and neutropenia 
from inhibition of JAK2 [3]. Another potential risk of immunosuppressive JAKinibs is 
increased risk of malignancies, although studies in RA patients have not shown 
increased risk of haematological cancers or solid tumours after long-term treatment 
with ruxolitinib [11]. 
While on-going development of JAKinibs with greater isoform-selectivity, such as 
JAK1-selective inhibitor filgotinib [12], could mitigate some of these issues , increasing 
selectivity may come at a price of reduced efficacy as autoimmune and chronic 
inflammatory diseases typically display imbalances in multiple cytokine pathways. 
Therefore, there is a need for new strategies acting via alternative mechanisms to 
target JAK-STAT signalling while minimising adverse reactions. 
 
SOCS proteins: inducible inhibitors of cytokine signalling 
One mechanism that has evolved to limit JAK-STAT signalling involves suppressor of 
cytokine signalling (SOCS) proteins, inducible gene products that inhibit JAK-STAT 
signalling as part of a negative-feedback loop. There are eight SOCS family members 
(SOCS1-7 and cytokine-inducible SH2-containing protein (CIS)). SOCS1 and SOCS3 
are the most extensively characterised members. Each comprises an N-terminal 
domain, which includes a kinase inhibitory region (KIR), a central SH2 domain and 
a C-terminal SOCS box domain (Figure 2A) [13]. SOCS proteins use a range of 
mechanisms to inhibit cytokine signalling. Thus while the KIR and SH2 domain of 
SOCS1 can directly bind the JAK kinase domain to inhibit phosphorylation (Figure 2B) 
[14], the CIS SH2 domain binds directly to JAK-phosphorylated cytokine receptors to 
block STAT recruitment [13]. In contrast, SOCS3 targets cytokine receptor complexes, 
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including those for IL-6 family cytokines containing the signalling receptor gp130, to 
inhibit JAK-STAT signalling. Upon binding phosphorylated Tyr759 (Tyr757 in mouse) 
in gp130 via its SH2 domain, the SOCS3 KIR associates with gp130-associated JAKs 
to non-competitively inhibit kinase activity (Figure 2B) [15]. 
In addition, the SOCS box motif enables formation of an elongin-cullin-SOCS3 E3 
ubiquitin ligase complex that targets bound substrates for polyubiquitylation and 
proteasomal degradation. SOCS3 binds the cullin5 scaffold protein in part via an 
elongin B/C dimer. Cullin5 also binds the Really Interesting New Gene (RING) domain-
containing protein Rbx2, which enables interaction with an E2 ubiquitin-conjugating 
enzyme (Figure 2A). Several protein families with roles in ubiquitylation have since 
been shown to include SOCS box domains which are critical for their function [16] [Box 
1]. Targets for SOCS3-mediated ubiquitylation include JAKs and cytokine receptors 
[13] and mice in which the SOCS box domain has been deleted have specific 
immunological defects, suggesting ubiquitylation-dependent roles for SOCS3 in these 
processes [17]. 
 
Cavin-1 and CUEDC2: a new class of SOCS regulators  
Interactions of SOCS1 and SOCS3 with target cytokine receptors, JAKs and proteins 
required to form a functional E3 ubiquitin ligase have been structurally defined 
[14,15,18]. In contrast, mechanisms for post-translational control of SOCS3 are poorly 
understood. 
However, evidence has now emerged of additional SOCS3-interacting proteins 
required for optimal inhibition of cytokine signalling. These are cavin-1, an essential 
component of caveolae [19], and CUEDC2 (CUE [coupling of ubiquitin to ER 
degradation] domain-containing protein 2), known primarily through its role in cell cycle 
control [20,21]. Cavin-1 was identified in a search for new SOCS3 targets by 
comparing profiles of ubiquitylated proteins from wild-type (SOCS3+/+) and SOCS3 
homozygous knockout (SOCS3−/−) mouse embryonic fibroblasts (MEFs). However, 
immunoblotting experiments in both SOCS3+/+ and SOCS3−/− MEFs as well as wild 
type and SOCS3-null AS-M.5 human angiosarcoma-derived endothelial cells (ECs) 
demonstrated that loss of SOCS3 protein reduced cavin-1 protein expression in the 
absence of any decrease in mRNA. Thus, SOCS3 stabilised cavin-1 protein levels. 
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Cavin-1 is essential for maintaining the stability of caveolae such that cavin-1 deletion 
triggers a parallel loss of caveolin-1 and a reduction in cell surface caveolae. Thus, 
SOCS3 deletion triggered reductions in cavin-1 and caveolin-1 proteins which reduced 
the number of cell surface caveolae detectable in SOCS3-null AS-M.5 ECs [22]. 
Interestingly, interaction with cavin-1 required the SOCS3 SH2 domain but was 
independent of its ability to bind Tyr-phosphorylated targets. Instead, cavin-1 binding 
required a PEST sequence that links conserved motifs found in almost all SH2 
domains. PEST sequences are unstructured regions involved in multiple cellular 
processes through controlling protein–protein interactions and protein turnover. 
Previous work had already implicated the SOCS3 PEST sequence in the control of 
SOCS3 protein turnover without altering its ability to inhibit JAK-STAT signalling. As 
well as SOCS3, a PEST sequence is also present at the same position within the CIS 
SH2 domain, which also interacted with cavin-1. Therefore, the PEST sequence within 
the SOCS3 SH2 domain is required for interaction with cavin-1 and may control cavin-
1 interaction with CIS [22]. 
Subcellular fractionation experiments revealed that cavin-1 and SOCS3 are present in 
cytosolic and membrane fractions, and that loss of cavin-1 shifted SOCS3 to the 
cytosolic fraction, suggesting that cavin-1 may play a role in membrane targeting. This 
was confirmed by confocal imaging experiments which demonstrated that while 
SOCS3-green fluorescent protein expressed in cavin-1-/- MEFs has a punctate 
distribution in the cytoplasm, reconstitution with a cavin-1-mCherry fusion protein 
resulted in their co-localisation at the plasma membrane, where SOCS3 can target 
Tyr-phosphorylated cytokine receptors. Time courses showed that the magnitude and 
duration of IL-6-stimulated STAT3 phosphorylation are greater in cavin-1-/- versus 
cavin+/+ cells. Importantly, SOCS3-dependent inhibition of STAT3 phosphorylation by 
IL-6 was abolished in cavin-1-/- MEFs, again suggesting a role for cavin-1 in localising 
SOCS3 to the plasma membrane for effective inhibition of signalling [22]. 
Several features of cavin-1 interaction with SOCS1 and SOCS3 are similar to those 
reported for CUEDC2 [23,24]. CUEDC2 has an established role in mitosis in which it 
controls release of the anaphase-promoting complex/cyclosome (APC/C) from 
checkpoint inhibition [20,21]. A search for transcription factors regulated by CUEDC2 
showed that it could inhibit STAT3 activation in response to IFN, IL-6 or forced co-
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expression of JAK1. Importantly, CUEDC2 can also suppress cytokine-stimulated 
Tyr1022/1023 phosphorylation and activation of JAK1, which is immediately 
downstream of both IFN receptor (IFNAR)1/IFNAR2 and gp130 signalling 
complexes responsible for IFN and IL-6 signalling respectively. Crucially, the 
inhibitory effect of CUEDC2 on STAT3 activation requires SOCS3, and CUEDC2 can 
interact directly with the SOCS3 SH2 domain in vitro [23]. Interestingly, the SOCS3 
SH2 region identified as being important for CUEDC2 interaction includes some of the 
PEST insert required for cavin-1 binding [22,23]. It also makes sense in that, like 
SOCS3, CUEDC2 would need to bind to the SOCS3 SH2 domain without blocking 
interaction with Tyr-phosphorylated targets such as gp130 (Figure 2A). However, 
CUEDC2 may potentiate SOCS3 inhibition by a mechanism distinct from cavin-1, as 
it stabilises SOCS3 by enhancing SOCS3-elongin C interaction to reduce SOCS3 
ubiquitylation [23]. Moreover, unlike SOCS3, SOCS1 contains a PEST motif within its 
N-terminal region rather than the SH2 domain [25]. In addition, there is no clear effect 
of cavin-1 on SOCS3 stability [22]. Also, in contrast to cavin-1 and SOCS3, CUEDC2 
is found in the nucleoplasm as well as the cytosol [26]. Thus CUEDC2 may stabilise 
specific intracellular pools of SOCS1 and SOCS3 so that there is more available for 
interaction with other targets, including plasma membrane-localised receptor 
complexes following cytokine stimulation. 
 
Exploiting SOCS interactions as new therapeutic targets 
Many studies have demonstrated that loss of SOCS1 and SOCS3 expression in 
myeloid cells and T cell subsets can enhance anti-tumour immunity [27]. Therefore, 
development of small molecules that can block SOCS1- and SOCS3-mediated 
inhibition of JAK-STAT signalling in myeloid and T cells represents one way to achieve 
this. Crucially, there is now detailed structural information available for both SOCS1 
and SOCS3 interaction with JAKs and other components required for inhibition of 
cytokine signalling to inform these efforts. These each provide a detailed picture of 
SOCS KIR motif interaction with a GQM motif present in the JAK JH1 catalytic domain 
required for SOCS-mediated inhibition of JAK activity (Figure 2B) [14,15]. Cell-
permeable peptide mimetics of SOCS1 function based on the KIR motif have already 
been developed that inhibit JAK-STAT signalling and have efficacy in murine models 
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of relapse-remitting multiple sclerosis [28] and autoimmune uveitis [29] as well 
as an ex vivo model of psoriasis [30]. Some of the observed efficacy may also be due 
to additional inhibition of NF-B-mediated pro-inflammatory responses via SOCS1 
interaction with and degradation of adaptor protein “MyD88-adaptor-like” (Mal) [31]. 
Whatever the mechanisms involved, functional assays suggest that current SOCS1 
mimetic peptides have micromolar affinities and therefore require optimisation to 
increase target affinity. With detailed structural information available, this could now 
be achieved by structure-based design and molecular docking approaches that could 
also facilitate virtual screening to identify promising compounds from chemical 
databases for in vitro validation as SOCS mimetics [32,33]. 
The interaction of the SOCS1 and SOCS3 KIR motifs with the JAK JH1 domain 
substrate binding site and activation loop also support an approach for development 
of SOCS antagonists using JAK-derived peptides [14,15,28]. Development of SOCS1 
antagonists using this strategy has focused on cell-permeable peptides based on the 
JAK2 JH1 activation loop (L1001PQDKEpYYKVKEP, pY=phosphorylated Tyr). As 
SOCS1 is a potent negative feedback inhibitor of anti-viral IFN signalling [34–36], 
SOCS1 antagonists would be predicted to enhance anti-viral effects through 
potentiation of cellular IFN responses. In support of this approach, a SOCS1 
antagonist has demonstrated anti-viral efficacy. In vivo, this is manifest as enhanced 
IFN and protective immune responses which reduce viral replication in infected cells 
[37]. 
While the above approaches exploit SOCS/JAK interactions, the identification of 
CUEDC2 and cavin-1 as regulators of SOCS function and stability represent another 
approach. As both cavin-1 and CUEDC2 enhance SOCS3 function (and SOCS1 
function in the case of CUEDC2), small molecules that block SOCS/CUEDC2 or 
SOCS3/cavin-1 interactions should enhance JAK-STAT signalling from specific 
cytokine receptors by blocking SOCS-mediated negative feedback. Based on the 
successful exploitation of key protein-protein interactions (PPIs) for new cancer 
therapeutics currently in clinical trials, including nutlin-based inhibitors of p53/MDM2 
interaction and bromodomain-containing protein 4 (BRD4) inhibitors that block 
interaction with acetylated Lys residues on target histones and transcription factors 
[38,39], the development of novel orthosteric small molecule SOCS PPIs for 
therapeutic applications is achievable. An important step forward would be crystal 
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structures of SOCS3 or its SH2 domain with either full length cavin-1, as multiple 
regions on cavin-1 appear to be required for interaction [22], or the CUEDC2 CUE 
domain that binds SOCS1 and SOCS3 [23,24]. This is because several key regions 
within the SOCS3 SH2 domain, including the PEST motif, are disordered and may 
therefore require interaction with binding partners to obtain high resolution structural 
information, similar to the increased ordering of the SOCS1 KIR observed when bound 
to JAK versus the lack of detectable electron density in its absence [14]. However, in 
the absence of structural information, overlapping peptide array technologies could 
be applied to identify and optimise high affinity SOCS-derived sequences that can 
function as SOCS/CUEDC2 or SOCS/cavin-1 PPI antagonists similar to approaches 
used for other proteins [40]. Identification of key regions within the CUE domain 
responsible for interaction with SOCS1 and SOCS3 would also allow for the 
development of optimised peptides that can mimic the effect of CUEDC2 in blocking 
SOCS ubiquitylation and thus act as SOCS stabilisers to enhance their expression 
and function [23,24]. In the case of SOCS3 stabilisation, this could be an alternative 
approach for chronic inflammatory conditions currently managed with JAKinhibs and 
anti-IL-6 receptor biologics, including RA, by enhancing SOCS3 expression and 
function to potentiate negative feedback inhibition of IL-6 signalling. In support of this 
approach, periarticular injection of a recombinant adenovirus encoding SOCS3 has 
been shown to reduce the severity of arthritis and joint swelling in two murine models 
of RA more effectively than a dominant-negative STAT3 adenovirus [41]. 
Finally, identification of novel mechanisms by which JAK-STAT signalling is regulated 
may also reveal opportunities to control signalling in new indications. One example is 
pulmonary arterial hypertension (PAH), a rare but devastating condition with a poor 
prognosis [42]. While PAH-targeted therapies, including prostaglandin receptor 
agonists, phosphodiesterase-5 inhibitors, endothelin receptor antagonists and soluble 
guanylate cyclase stimulators, used alone or in combination can improve functional 
capacity and haemodynamics, they act predominantly as vasodilators to relieve 
symptoms, do not target key features of PAH pathogenesis and produce only modest 
reductions in mortality [42,43]. Studies in rodent models have shown that IL-6 is 
necessary and sufficient for the development of PAH, with significantly increased 
expression and function of membrane-bound IL-6R being observed in pulmonary 
arterial smooth muscle cells from pre-clinical PAH models and PAH patients [44,45]. 
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Consistent with a role for IL-6R in disease progression, treatment with either a 
neutralizing anti-IL6R antibody or a non-peptide IL-6R antagonist [46], reversed PAH 
in two rodent models of the disease [44]. However, while small molecule JAKinhibs 
and anti-IL-6R biologics could be re-purposed for PAH, development of additional 
therapeutics is essential as PAH patients can become resistant after initial 
responsiveness to new interventions [42]. Therefore, peptides targeting novel SOCS 
interactors such as cavin-1 and CUEDC2 that act as SOCS3 mimetics or stabilisers 
to enhance inhibition of IL-6-stimulated pro-inflammatory signalling could be used as 
starting points for the development of more drug-like molecules potentially via 
inhalation, which offers an attractive option for PAH by allowing drug delivery direct to 
the lungs [47]. 
SOCS3 mimetics might also be useful for a range of conditions in which STAT3 is 
hyperactivated due to epigenetic silencing of the SOCS3 gene. One such condition is 
cholangiocarcinoma (CCA). Due to late clinical presentation and the lack of effective 
treatments, survival rates are only 10-40% over 5 years [48,49]. Therefore, there is a 
need for effective therapies for this devastating condition. STAT3 is hyperactivated in 
CCA epithelial cells, resulting in cellular resistance to apoptosis and induction of 
epithelial-to-mesenchymal transition (EMT) [50]. Importantly, ectopic expression of 
SOCS3 blocks IL-6 activation of STAT3 and EMT in vitro, while SOCS3 expression in 
vivo decreases metastasis, an effect associated with reduced STAT3 activation, N-
cadherin and vimentin expression, and induction of E-cadherin [51]. In addition to the 
repurposing potential of anti-IL-6R biologics and JAKinhibs currently used for 
treatment of RA, development of SOCS3 mimetics also has the potential to reverse 
the detrimental effects of STAT3 activation in CCA to inhibit disease progression. 
It should be noted that targeting PPIs to enhance SOCS function is not without 
potential pitfalls. For example, PPIs targeting the cavin-1 binding site on SOCS3 have 
the potential to uncouple SOCS3 from cavin-1, which could potentially destabilise 
cavin-1 in cell types in which cavin-1 is abundantly expressed, including adipocytes 
and skeletal muscle [19,22]. As loss of functional cavin-1 in mice and humans triggers 
lipodystrophy and insulin resistance, these would have to be monitored as potential 
adverse reactions to drugs targeting the SOCS3/cavin-1 interface. 
 
11 
 
CONCLUDING REMARKS AND FUTURE DIRECTIONS 
Development of small molecule JAKinhibs and cytokine-targeted biologics has 
demonstrated that inhibition of the JAK-STAT pathway can be an efficacious way to 
treat inflammatory and autoimmune diseases. However, adverse effects and 
resistance to some of these regimes emphasises the need to develop more targeted 
therapeutics with novel mechanisms of action to overcome these limitations. 
Identification of molecular mechanisms by which JAK-STAT signalling is regulated 
may also reveal opportunities to control signalling in new indications. 
Peptides targeting novel SOCS interactors such as cavin-1 and CUEDC2 that act as 
SOCS1 or SOCS3 mimetics or antagonists could be used as starting points for the 
development of more drug-like molecules for diseases in which these proteins play a 
role. One disease area in which SOCS3 mimetics have potential is RA, for which JAK 
inhibits and anti-IL-6R biologics are already options for those patients resistant to first 
line therapies. 
Finally, the interaction of SOCS3 with cavin-1 represents a previously unforeseen link 
between JAK-STAT signalling and mechanoprotection. Several studies have shown 
that caveolae maintain plasma membrane integrity following mechanical stress 
(reviewed in [19]). Stretching of the plasma membrane causes an ATP- and actin-
independent flattening of caveolae to buffer increased membrane tension, triggering 
a dissociation of cavins from the plasma membrane. Therefore loss of caveolin-1 
expression in vascular endothelial cells results in a loss of caveolae and increased 
sensitivity to mechanical damage in vitro and in vivo [52,53]. Given that SOCS3 
deletion destabilises cavin-1 and results in a loss of plasma membrane caveolae, this 
suggests a new role for SOCS3 and CIS in controlling mechanoprotective capacity via 
interaction with and stabilisation of cavin-1. 
In summary, the identification of new mechanisms to control JAK-STAT signalling 
provides a starting point both for generation of new therapeutics for indications in 
which current options have significant limitations. However, exploiting these 
opportunities fully will require a greater molecular understanding of the mechanisms 
involved (see Outstanding Questions). 
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BOX 1: The SOCS box superfamily 
While initially identified in the SOCS family, SOCS box domains are found in over 30 
genes within the human genome. All SOCS box-containing proteins have E3 ubiquitin 
ligase activity through formation of a complex with Cul5 and the RING domain protein 
Rbx2 similar to SOCS3 (Figure 2A). The SOCS box-superfamily comprises 6 
subgroups which are defined by additional domains responsible for controlling 
localisation and function (Figure I). As the SOCS family is described elsewhere, this 
section will provide an overview of other key families. 
Ankyrin repeat and SOCS box (ASB) family Comprising 18 members (ASB1-18), ASB 
proteins consist of between 1-12 N-terminal ankyrin repeats upstream of a C-terminal 
SOCS box. Ankyrin repeats mediate protein-protein interactions and thus determine 
the spectrum of substrates for individual ASB family members. ASB proteins can form 
oligomers with each other and additional E3 ubiquitin ligase complexes, although the 
functional significance of these interactions is unclear [54]. Key substrates of this 
family include signalling proteins such as insulin receptor substrate 4 (IRS4), an 
adaptor protein important for insulin and leptin receptor signalling in brain targeted by 
ASB4, and tumour necrosis factor receptor (TNFR) 2, which is targeted for degradation 
by ASB3 thereby inhibiting TNF-mediated apoptotic responses in Jurkat cells [55]. 
WD repeat and SOCS box-containing protein (WSB) family While there are 2 members 
of this family (WSB1-2), only WSB1 has been studied in any detail. WSB1 contains 8 
WD40 repeats, which determine interaction with substrates, linked to a C-terminal 
SOCS box domain. The WD40 repeats form a four stranded anti-parallel beta sheets 
or “blades” which typically come together to form a propeller structure . WSB1 
substrates include homeodomain-interacting protein kinase 2 (HIPK2), a regulator of 
gene transcription which prevents apoptosis, and the tumour suppressor von Hippel-
Landau (VHL), which forms part of a separate E3 ubiquitin ligase complex that controls 
transcriptional responses to hypoxia [56]. 
SPRY domain-containing SOCS box protein (SPSB) family The 4 SPSB family 
members (SPSB1-4) each consist of an N-terminal SplA/ryanodine receptor (SPRY) 
domain responsible for target protein interaction linked to a C-terminal SOCS box 
domain. A well-characterised substrate of SPSB1, 2 and 4 is inducible nitric oxide 
synthase (iNOS), a key effector of the innate immune response. By promoting iNOS 
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protein degradation, SPSB proteins prevent the accumulation of cytotoxic levels of 
nitric oxide that could damage ultimately host tissue [57,58]. 
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Figure Legends 
Figure 1: JAK structure and activation of JAK-STAT signalling 
A: Domain structure common to al JAK isoforms. The locations of Tyr phosphorylation 
sites within the JH1 domain activation loop required for kinase activity are shown. 
These correspond to Tyr1034,1035 (human JAK1), Tyr1007,1008 (human JAK2), 
Tyr980,981 (human JAK3) and Tyr1054,1055 (human Tyk2). 
B: Interaction of a cytokine with its membrane-bound receptor complex triggers 
activation of receptor-bound JAKs, which then phosphorylate the receptor on key 
cytoplasmic Tyr residues. These act as docking sites for SH2 domain-mediated 
interactions with STAT proteins. JAKs phosphorylate recruited STATs on a single Tyr 
residue in the C-terminal domains, which allows the STATs to dissociate from the 
receptor and dimerise. Dimeric STAT complexes then translocate to the nucleus, bind 
target DNA and initiate gene transcription. 
 
Figure 2: SOCS3 domain structure and functional interactions 
A: SOCS3 domains include an extended N-terminal region, which includes a kinase 
inhibitory region (KIR) present in both SOCS1 and SOCS3, a central SH2 domain and 
a SOCS box, which contains sub-domains for binding elongins B and C and cullin 5 
(Cul5) proteins. These link with Rbx2 to form a functional E3 ubiquitin ligase complex 
which interacts with an E2 ubiquitin-conjugating enzyme to transfer ubiquitin to bound 
targets. Targets for SOCS3-mediated ubiquitylation bind to the phospho-Tyr binding 
pocket of the SH2 domain. The SH2 domain is also the site for interaction with novel 
regulators cavin-1 and CUEDC2. 
B: Ribbon diagram of the structure of a JAK1 (beige)-SOCS1-(red)-ADP (green) 
complex. The SOCS1 construct used did not contain a SOCS box. The broken circle 
highlights SOCS1 KIR and SH2 domain interactions with the C-terminal lobe of the 
JAK1 JH1 domain. The N-terminal JAK1 JH1 domain lobe are also indicated, along 
with an extended SH2 subdomain (ESS) motif present in SOCS1. The inset shows the 
SOCS1 KIR (red) overlaid with the SOCS3 KIR (green) within the JAK1 JH1 domain. 
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The GQM motif required for SOCS binding is indicated. Residue numbering refers to 
the human sequences. Figures adapted from [14] with permission. 
 
Box 1, Figure I: SOCS box family protein: Domain structures of representative 
members from each of the six families of SOCS box family proteins. While members 
from each family can form function E3 ubiquitin ligases via the SOCS box, each family 
is defined by the other domains which define interactions with the substrates targeted 
by each complex. SH2, Src homology 2; ANK, ankyrin repeat; WD, WD repeat; SPRY, 
SPla/Ryanodine receptor domain; LRR, Leucine-rich repeat. 
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Glossary 
Activation loops: flexible loop structures within the catalytic domains of protein 
kinases. Most kinases have one or more residues in the activation loop that undergo 
phosphorylation as a prerequisite for activation of kinase activity. 
Ankylosing spondylitis: condition in which chronic inflammation promotes the 
deposition of calcium where ligaments attach to vertebrae, and may eventually result 
in fusion of adjacent vertebrae. 
APC/C: a large multi-protein complex of 11–13 subunits which ubiquitylates specific 
cell cycle proteins, thereby tagging them for degradation by the proteasome. 
Autoimmune disorders: diseases in which the immune system mistakenly 
recognises body tissues as foreign material and attacks them. Examples include RA, 
multiple sclerosis and type 1 diabetes mellitus. 
Autoimmune uveitis: chronic inflammation of the uvea, which is the middle layer of 
pigmented vascular structures of the eye, triggered by an autoimmune reaction. 
Autosomal dominant hyper IgE syndrome: a rare immunodeficiency disorder 
caused by a single abnormal copy of the STAT3 gene, and characterised by elevated 
levels of IgE. Patients are susceptible to opportunistic bacterial infections of the skin 
and lungs. 
Biologics: engineered protein- or nucleic acid-based drugs produced using biological 
processes involving recombinant DNA technology. 
CAR T cell-induced cytokine release syndrome: adverse effect of treatment of B 
cell malignancies with CAR T cells, in which a rapid and pronounced release of 
multiple pro-inflammatory cytokines triggers fever, hypotension and respiratory 
insufficiency. 
Caveolae: 50–100 nanometre flask-shaped plasma membrane invaginations found in 
many vertebrate cell types, and especially abundant in endothelial cells, adipocytes 
and muscle cells. 
CCA: a malignant neoplasm originating from epithelial cells lining the biliary tracts. 
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Dominant-negative: a mutated gene product that antagonises the function of the wild-
type/normal version. 
E3 ubiquitin ligase: defined as a protein that recruits an E2 conjugation enzyme that 
has been loaded with ubiquitin, a small protein found in all eukaryotic organisms. After 
binding a protein substrate, the E3 ligase catalyses the transfer of ubiquitin from the 
E2 to the substrate. 
EMT: epithelial-to-mesenchymal transition. This describes the process in which a 
polarised epithelial cell, immobilised to a basement membrane via its basal surface, 
undergoes biochemical changes that enable it to assume a mesenchymal cell 
phenotype, characterised by enhanced migration, invasiveness and resistance to 
apoptosis. Completion of EMT is marked by degradation of the underlying basement 
membrane and migration of the mesenchymal cells away from the epithelial layer. 
FERM domain: typically involved in localising proteins to the plasma membrane via 
interaction with integral membrane proteins. 
Giant cell arteritis: serious condition in which arteries, particularly those at the side 
of the head, become inflamed. This results in vessel narrowing, which interrupts blood 
flow. Symptoms include severe headache, dizziness and loss of vision. 
Herpes zoster: also known as shingles, this is caused by the Varicella-zoster virus, 
which is also the causative agent of chicken pox. Once a person has had chicken pox, 
the virus remains in nerve cells near the spine. Herpes zoster develops when the virus 
is re-activated. 
IFNs: a group of cytokines released by host cells in response to pathogens such as 
viruses, bacteria and parasites. The name derives from their capacity to “interfere” 
with viral replication and thus protect cells from viral infection. 
JH: refers to seven regions (JH1-7) of structural similarity between the four JAK 
isoforms (JAK1-3, Tyk2). 
KIR: a sequence within each of SOCS1 and SOCS3 that directly interacts with 
receptor-bound JAKs to inhibit kinase activity. 
MPNs: a group of four rare bone marrow disorders (chronic myeloid leukaemia, 
polycythaemia vera, essential thrombocythaemia, myelofibrosis) that cause an 
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increase in the numbers of specific blood cell types. MPNs are distinguished from each 
other based on symptoms and the type of blood cells affected. 
Multicentric Castleman’s disease: condition in which there is abnormal growth of 
cells within multiple lymph nodes. 
Neutropenia: deficiency of neutrophils, which play an important role in fighting 
infection by destroying invading bacteria and fungi. 
Orthosteric: refers to a primary binding site, as opposed to an “allosteric” binding site 
which is spatially distinct from the primary/orthosteric site. 
Overlapping peptide array: Describes an organised pattern of peptides spotted onto 
a glass or cellulose support. In an overlapping peptide array, a protein’s full sequence 
is subdivided into partially overlapping 10-20 residue peptides. These arrays can then 
be used for several downstream applications, including identification of protein-protein 
interaction sites. 
PEST sequence: Pro-Glu-Ser-Thr-enriched sequences found in many proteins and 
which play important roles in controlling protein half-life. 
Psoriasis: chronic autoimmune condition characterised by the presence of dry, itchy 
and inflamed patches of skin. The most common form is plaque psoriasis which 
presents as red patches topped with white scaly skin. 
PAH: defined as high blood pressure in the small blood vessels that supply the lungs 
(pulmonary arterioles). Pulmonary arteriole walls become thick, stiff and resistant to 
expansion to allow blood flow. The reduced blood flow makes it harder for the right-
hand side of the heart to pump blood through the arteries, ultimately causing heart 
failure. 
Relapse-remitting multiple sclerosis: autoimmune condition in which the sheath of 
myelin that protects nerve cells is damaged. This disrupts communication in the 
nervous system, resulting in a range of physical symptoms including muscle 
weakness, blindness and poor coordination. In the relapse-remitting form, symptoms 
occur in isolated attacks. 
Repurposing: application of approved drugs to treat a different disease. Also termed 
“repositioning”. One of the best known examples is sildenafil, which was originally 
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developed as an anti-hypertensive medicine but has been repurposed for treatment of 
erectile dysfunction and PAH. 
RA: a long-term autoimmune condition that typically causes pain, swelling and 
stiffness in joints of the hands, feet and wrists. Other organ systems can be also 
affected, including the blood and cardiovascular systems. 
Severe combined immunodeficiency: a group of rare genetic disorders that cause 
major abnormalities of the immune system, leading to greatly increased risk of 
infection and other life-threatening complications. 
SH2 domain: a structurally conserved protein module that allows interaction with 
phosphorylated tyrosine residues on other proteins. 
Thrombocytopenia: deficiency of platelets required for effective clotting following 
tissue damage. Therefore, thrombocytopenia can lead to easy or excessive bruising 
(purpura), prolonged bleeding times and the appearance of red or purple blood spots 
in the skin (petechiae). 
Outstanding Questions 
Are cavin-1 and CUEDC2 members of a wider family of SOCS1 and SOCS3-
interacting regulatory proteins that control SOCS function and/or subcellular 
localisation? 
 
To what extent is interaction with cavin-1 and CUEDC2 shared within the SOCS 
family?  
 
Does SOCS3 maintain caveolae directly through its interaction with cavin-1? And does 
SOCS3 play a role in determining cellular resistance to mechanical damage in vivo by 
regulation of caveolae? 
 
 
Palmer Outstanding Questions
EDITOR IN CHIEF 
We have restructured the manuscript in the suggested running order, in the process 
taking out a lot of mechanistic detail from the introductory sections and reducing the 
total word count in line with the recommendation. The length of the main text of the 
article is now 3460 words and includes 58 references. 
We have also simplified the figures as suggested (particularly Figs 1A and B), taking 
out extraneous detail and better integrating them into the main text so they illuminate 
the key points being communicated. 
In terms of the specific comments in the original manuscript:- 
1. The introductory paragraph now has more appropriate references. 
2. The article is much less focused on IL-6 so much of this detail has been removed. 
3. In Fig 1A, a generic JAK domain structure has replaced the original figure. The 2 
phosphorylation sites in the figure responsible for activation of all 4 JAK isoform 
are now given in the legend. For clarity, we have also removed the term 
“pseudoSH2” throughout the article. 
 
REVIEWER 1 
We thank the reviewer for describing our article as “very well written and timely”. With 
respect to specific points:- 
1. Cbl E3 ligases – while it is an excellent suggestion to include some information 
about this class of E3 ligases which also target JAKs, the restricted word length of 
the Opinion article means we cannot include this. 
2. The text on JH1-JH2 interactions has now been removed. 
3. CIS1 has been corrected to CIS. 
 
REVIEWER 2 
We thank the reviewer for describing our article as “well written and thoughtful”. With 
respect to specific points:- 
1. Other approved biologics – we have reduced the focus on IL-6 throughout the 
revised manuscript. In reference to the reviewer’s specific point, we have now 
included references to approved IL-17 and IL-5 biologics (page 3). 
2. JAK inhibitors – we have now included anaemia as a common side effect as 
requested (page 3). We have also included filgotinib as a JAK1 inhibitor in the 
context of reducing side effects with more selective drugs (page 3). The word 
Response to Reviewers
restriction on an Opinion article means we cannot go into depth on this topic. 
Finally we mention how increased risk of infection is a side effect of biologics such 
as tociluzimab and JAK inhibitors (page 3). 
3. Cavin-1 – the reviewer makes the valid point that cavin-1 expression in immune 
cells is limited. However our manuscript proposes targeting the distinct regions on 
SOCS3 that interact with cavin-1 and CUEDC2 as approaches to enhance 
endogenous SOCS3 function. While these approaches are independent of 
whether cavin-1 or CUEDC2 are co-expressed with SOCS3, given the importance 
of SOCS3 in determining cavin-1 stability, small molecules that bind SOCS3 and 
block interaction with co-expressed cavin-1 may impact function of those cells in 
which cavin-1 is abundantly expressed. This is now elaborated on p11. 
 
 
REVIEWER 3 
We appreciate the reviewer’s criticisms and have taken them on board as follows:- 
1. Figures – in response to feedback from the Editor in Chief to simplify the 
background section, we have changed Figure 1A to show a simplified scheme for 
cytokine receptor activation of the JAK-STAT pathway. In Figure 3, the construct 
used for SOCS1-JAK1 JH1 domain structural studies did not contain a SOCS box. 
This information is now included in the legend for clarity. In terms of similarity to a 
previously published figure (singular), the reviewer is referring to a schematic of 
the domain structure of JAK1 and JAK2. We have simplified Figure 1A in line with 
the Editor in Chief’s feedback and, as a result, it is now distinct. 
2. We have incorporated some clarification to describe how modulation of SOCS 
function would alter cell function to alleviate disease. For example, when 
discussing anti-viral effects of SOCS1 antagonists, this is discussed as a 
consequence of enhancing anti-viral interferon responses by blocking SOCS1-
mediated negative feedback of interferon signaling (page 8). Likewise, we discuss 
how SOCS3 agonists or stabilisers could be developed for RA (page 9) and PAH 
(page 10) through potentiation of SOCS3-mediated inhibition of pro-inflammatory 
IL-6 signalling. 
 
REVIEWER 4 
We thank the reviewer for describing our article as “well organized and written”. With 
respect to specific points:- 
1. SOCS as targets is counterintuitive – we take the point that receptor-targeted 
small molecules generated by targeting cytokine receptors would be a more 
conventional approach to generate selective therapeutics. However, we do not 
believe this is enough of an argument to discount SOCS-targeted therapeutics. IN 
fact, a criticism of targeting “more broadly acting downstream regulators” could 
also be levelled at currently approved JAKinibs, which non-selectively act 
downstream of multiple JAK-STAT-mobilising receptors yet demonstrate efficacy 
in a range of disorders (pages 3-4 and associated references). Also, our 
manuscript is now being considered as an Opinion piece and is therefore a more 
appropriate platform for proposing our perspective. 
2. As literature in this area is limited, we have been advised by the Editor in Chief to 
reconfigure our manuscript as a shorter Opinion piece, which we have now done. 
Also, while many of the experiments in the supporting literature used 
overexpression systems to identify and characterize key observations, in the case 
of SOCS3/cavin-1, these were validated in cells deficient in endogenous SOCS3 
and cavin-1. To be frank, the work would not have been published if experiments 
in overexpression systems were not validated in cells expressing the endogenous 
proteins. 
3. Given that the focus of the article is SOCS proteins, we respectfully disagree with 
the reviewer that the Box material is not a good fit. In support of this, none of the 
other referees commented on this. 
4. Inclusion of the SHP2 binding site in Figure 1A – in response to the Editor in 
Chief’s feedback, we have reduced the focus on IL-6 and have instead produced 
a new Figure 1A which shows a simplified scheme for cytokine receptor activation 
of the JAK-STAT pathway. 
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